Hims and Hers stock surges 10% on analyst upgrades By Investing.com

Hims & Hers struck a partnership with Novo Nordisk to sell Ozempic and Wegovy (including a new pill form) and Novo dropped its lawsuit, sending HIMS shares up ~49% Monday and 10% Tuesday. Multiple analyst upgrades followed: BofA to Neutral with a $23 PT (from $12.50) applying a 23x CY26E EV/EBITDA including GLP‑1 revenue; Citi to Neutral with $24 PT (from $13.25); Needham to Buy with a $30 PT. The deal materially reduces legal risk and fills revenue gaps from compounded GLP‑1s, though Hims will face restrictions on its compounding business and a limited set of customers permitted to remain on compounded products.

Analysis

The market move is less about a single deal and more about re-pricing structural scarcity and channel control in the GLP‑1 ecosystem. Branded manufacturers gain two levers simultaneously: price stickiness from limited compounding substitutes and bargaining leverage with payers; that math can add high-margin incremental EBITDA over 12–24 months even if unit growth moderates.

Second‑order supply effects matter more than headlines. Expect API and CMO utilization to tighten over 6–12 months, forcing small players to pay up or endure out‑of‑stock; companies owning capacity (and the logistics channels that prioritize branded finished-dose forms) will capture outsized margin. Conversely, compounding-heavy distribution and low-capital telehealth operators face margin compression as their low‑cost substitute is constrained.

Key risks are regulatory and reimbursement shocks rather than pure commercial competition. A single adverse-safety signal, a class-level FDA labeling change, or a coordinated payer step‑therapy/rebate push can reverse multiple quarters of rerating within weeks. Monitor three near-term catalysts: manufacturing utilization reports (CMO commentary) over the next 2–3 quarters, payer prior‑authorization rollouts over 6–12 months, and any safety/regulatory headlines that can compress multiples rapidly.

Key Decisions for Investors

• NVO — Buy (1–2% NAV) into any pullbacks; horizon 12–24 months. Rationale: asymmetric payoff from branded pricing and channel control; target 25–40% upside if utilization and pricing persist. Place a tactical stop at ~12% to protect against rapid regulatory headlines.
• NVO — Buy Jan‑2028 LEAP calls (size 0.5–1% NAV) to express multi‑year convexity. Max loss = premium; upside >3x if branded pricing and CMO tightness persist. Use LEAPs to avoid short‑term volatility and capture sustained margin expansion.
• NVO — If already long, sell 4–6 month covered calls ~10–12% OTM to monetize near‑term volatility while retaining most upside; alternatively implement a collar if worried about regulatory tail risk. This generates 4–8% premium cushion over the option period while capping part of the upside.